The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture
Open accessAbstract
Coronaviruses can cause respiratory and enteric disease in a wide variety of human and animal hosts. The 2003 outbreak of severe acute respiratory syndrome (SARS) first demonstrated the potentially lethal consequences of zoonotic coronavirus infections in humans. In 2012, a similar previously unknown coronavirus emerged, Middle East respiratory syndrome coronavirus (MERS-CoV), thus far causing over 650 laboratory-confirmed infections, with an unexplained steep rise in the number of cases being recorded over recent months. The human MERS fatality rate of ∼30% is alarmingly high, even though many deaths were associated with underlying medical conditions. Registered therapeutics for the treatment of coronavirus infections are not available. Moreover, the pace of drug development and registration for human use is generally incompatible with strategies to combat emerging infectious diseases. Therefore, we have screened a library of 348 FDA-approved drugs for anti-MERS-CoV activity in cell culture. If such compounds proved sufficiently potent, their efficacy might be directly assessed in MERS patients. We identified four compounds (chloroquine, chlorpromazine, loperamide, and lopinavir) inhibiting MERS-CoV replication in the low-micromolar range (50% effective concentrations [EC 50 s], 3 to 8 μM). Moreover, these compounds also inhibit the replication of SARS coronavirus and human coronavirus 229E. Although their protective activity (alone or in combination) remains to be assessed in animal models, our findings may offer a starting point for treatment of patients infected with zoonotic coronaviruses like MERS-CoV. Although they may not necessarily reduce viral replication to very low levels, a moderate viral load reduction may create a window during which to mount a protective immune response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Woo, P. C. Y., Lau, S. K. P., Lam, C. S. F., Tsang, A. K. L., Hui, S., Fan, R. Y. Y., Martelli, P. R., & Yuen, K. (2013) · Journal of Virology · doi:10.1128/jvi.02351-13 · Cited by 177
RetractedAngiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735
Self-citationIdentification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061 · cited 4×
“MERS-CoV infection in humans can cause clinical symptoms resembling SARS, such as high fever and acute pneumonia, although the two viruses were reported to use different entry receptors, dipeptidyl peptidase 4 (DPP4) (10) and angiotensin-converting enzyme 2 (ACE2) (11), respectively.”
BackgroundInfluentialChloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,811
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
Ge, X.-Y., Li, J.-L., Yang, X.-L., Chmura, A. A., Zhu, G., Epstein, J. H., Mazet, J. K., Hu, B., Zhang, W., Peng, C., et al. (2013) · Nature · doi:10.1038/nature12711 · Cited by 1,778
Woo, P. C. Y., Lau, S. K. P., Lam, C. S. F., Lau, C. C. Y., Tsang, A. K. L., Lau, J. H. N., Bai, R., Teng, J. L. L., Tsang, C. C. C., Wang, M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.06540-11 · Cited by 1,677
Effects of chloroquine on viral infections: an old drug against today's diseases
Savarino, A., Boelaert, J. R., Cassone, A., Majori, G., & Cauda, R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00806-5 · Cited by 1,268
de Groot, R. J., Baker, S. C., Baric, R. S., Brown, C. S., Drosten, C., Enjuanes, L., Fouchier, R. A. M., Galiano, M., Gorbalenya, A. E., Memish, Z. A., et al. (2013) · Journal of Virology · doi:10.1128/jvi.01244-13 · Cited by 1,236
Self-citationSARS: systematic review of treatment effects
Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217
Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation.
Wang, L. H., Rothberg, K. G., & Anderson, R. G. (1993) · The Journal of cell biology · doi:10.1083/jcb.123.5.1107 · Cited by 1,177
van Boheemen, S., de Graaf, M., Lauber, C., Bestebroer, T. M., Raj, V. S., Zaki, A. M., Osterhaus, A. D. M. E., Haagmans, B. L., Gorbalenya, A. E., Snijder, E. J., et al. (2012) · mBio · doi:10.1128/mbio.00473-12 · Cited by 914
Self-citationReusken, C. B., Haagmans, B. L., Müller, M. A., Gutierrez, C., Godeke, G.-J., Meyer, B., Muth, D., Raj, V. S., Vries, L. S.-D., Corman, V. M., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70164-6 · Cited by 734
Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases
Yang, H., Xie, W., Xue, X., Yang, K., Ma, J., Liang, W., Zhao, Q., Zhou, Z., Pei, D., Ziebuhr, J., et al. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030324 · Cited by 727
Middle East Respiratory Syndrome Coronavirus in Bats, Saudi Arabia
Memish, Z. A., Mishra, N., Olival, K. J., Fagbo, S. F., Kapoor, V., Epstein, J. H., AlHakeem, R., Durosinloun, A., Al Asmari, M., Islam, A., et al. (2013) · Emerging Infectious Diseases · doi:10.3201/eid1911.131172 · Cited by 716
Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
Haagmans, B. L., Al Dhahiry, S. H. S., Reusken, C. B. E. M., Raj, V. S., Galiano, M., Myers, R., Godeke, G.-J., Jonges, M., Farag, E., Diab, A., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70690-x · Cited by 671
Dyall, J., Coleman, C. M., Hart, B. J., Venkataraman, T., Holbrook, M. R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Jahrling, P. B., Laidlaw, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03036-14 · Cited by 660
A decade after SARS: strategies for controlling emerging coronaviruses
Graham, R. L., Donaldson, E. F., & Baric, R. S. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3143 · Cited by 655
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., & Ranst, M. V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.085 · Cited by 649
Self-citationHepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis
Blanchard, E., Belouzard, S., Goueslain, L., Wakita, T., Dubuisson, J., Wychowski, C., & Rouillé, Y. (2006) · Journal of Virology · doi:10.1128/jvi.00024-06 · Cited by 599
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Small molecules targeting severe acute respiratory syndrome human coronavirus
Wu, C.-Y., Jan, J.-T., Ma, S.-H., Kuo, C.-J., Juan, H.-F., Cheng, Y.-S. E., Hsu, H.-H., Huang, H.-C., Wu, D., Brik, A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403596101 · Cited by 521
Snijder, E. J., van der Meer, Y., Zevenhoven-Dobbe, J., Onderwater, J. J. M., van der Meulen, J., Koerten, H. K., & Mommaas, A. M. (2006) · Journal of Virology · doi:10.1128/jvi.02501-05 · Cited by 512
Self-citationA noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication
Ratia, K., Pegan, S., Takayama, J., Sleeman, K., Coughlin, M., Baliji, S., Chaudhuri, R., Fu, W., Prabhakar, B. S., Johnson, M. E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805240105 · Cited by 507
Rapid generation of a mouse model for Middle East respiratory syndrome
Zhao, J., Li, K., Wohlford-Lenane, C., Agnihothram, S. S., Fett, C., Zhao, J., Gale, M. J., Baric, R. S., Enjuanes, L., Gallagher, T., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323279111 · Cited by 452
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques
Falzarano, D., de Wit, E., Rasmussen, A. L., Feldmann, F., Okumura, A., Scott, D. P., Brining, D., Bushmaker, T., Martellaro, C., Baseler, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3362 · Cited by 445
Pfefferle, S., Schöpf, J., Kögl, M., Friedel, C. C., Müller, M. A., Carbajo-Lozoya, J., Stellberger, T., von Dall’Armi, E., Herzog, P., Kallies, S., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002331 · Cited by 415
Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS
Drexler, J. F., Corman, V. M., & Drosten, C. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2013.10.013 · Cited by 406
Virus taxonomy, 6th report of the International Committee on Taxonomy of Viruses.
(1995) · PubMed · Cited by 387
Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
Chan, J. F. W., Chan, K.-H., Kao, R. Y. T., To, K. K. W., Zheng, B.-J., Li, C. P. Y., Li, P. T. W., Dai, J., Mok, F. K. Y., Chen, H., et al. (2013) · Journal of Infection · doi:10.1016/j.jinf.2013.09.029 · Cited by 385
Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
Haagmans, B. L., Kuiken, T., Martina, B. E., Fouchier, R. A. M., Rimmelzwaan, G. F., van Amerongen, G., van Riel, D., de Jong, T., Itamura, S., Chan, K.-H., et al. (2004) · Nature Medicine · doi:10.1038/nm1001 · Cited by 381
Inoue, Y., Tanaka, N., Tanaka, Y., Inoue, S., Morita, K., Zhuang, M., Hattori, T., & Sugamura, K. (2007) · Journal of Virology · doi:10.1128/jvi.00253-07 · Cited by 369
From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses
Hilgenfeld, R., & Peiris, M. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.08.015 · Cited by 354
de Wilde, A. H., Raj, V. S., Oudshoorn, D., Bestebroer, T. M., van Nieuwkoop, S., Limpens, R. W. A. L., Posthuma, C. C., van der Meer, Y., Bárcena, M., Haagmans, B. L., et al. (2013) · Journal of General Virology · doi:10.1099/vir.0.052910-0 · Cited by 348
Self-citationAl-Tawfiq, J. A., Momattin, H., Dib, J., & Memish, Z. A. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2013.12.003 · Cited by 322
de Wit, E., Rasmussen, A. L., Falzarano, D., Bushmaker, T., Feldmann, F., Brining, D. L., Fischer, E. R., Martellaro, C., Okumura, A., Chang, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310744110 · Cited by 313
Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice
Keyaerts, E., Li, S., Vijgen, L., Rysman, E., Verbeeck, J., Van Ranst, M., & Maes, P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01509-08 · Cited by 311
Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
Falzarano, D., de Wit, E., Martellaro, C., Callison, J., Munster, V. J., & Feldmann, H. (2013) · Scientific Reports · doi:10.1038/srep01686 · Cited by 273
Pohjala, L., Utt, A., Varjak, M., Lulla, A., Merits, A., Ahola, T., & Tammela, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028923 · Cited by 270
Spread, Circulation, and Evolution of the Middle East Respiratory Syndrome Coronavirus
Cotten, M., Watson, S. J., Zumla, A. I., Makhdoom, H. Q., Palser, A. L., Ong, S. H., Al Rabeeah, A. A., Alhakeem, R. F., Assiri, A., Al-Tawfiq, J. A., et al. (2014) · mBio · doi:10.1128/mbio.01062-13 · Cited by 266
A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents
Madrid, P. B., Chopra, S., Manger, I. D., Gilfillan, L., Keepers, T. R., Shurtleff, A. C., Green, C. E., Iyer, L. V., Dilks, H. H., Davey, R. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060579 · Cited by 247
Cyclosporin A inhibits the replication of diverse coronaviruses
de Wilde, A. H., Zevenhoven-Dobbe, J. C., van der Meer, Y., Thiel, V., Narayanan, K., Makino, S., Snijder, E. J., & van Hemert, M. J. (2011) · Journal of General Virology · doi:10.1099/vir.0.034983-0 · Cited by 243
Self-citationHart, B. J., Dyall, J., Postnikova, E., Zhou, H., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Frieman, M. B., Holbrook, M. R., Jahrling, P. B., et al. (2014) · Journal of General Virology · doi:10.1099/vir.0.061911-0 · Cited by 211
Barnard, D. L., Day, C. W., Bailey, K., Heiner, M., Montgomery, R., Lauridsen, L., Chan, P. K., & Sidwell, R. W. (2006) · Antiviral Chemistry and Chemotherapy · doi:10.1177/095632020601700505 · Cited by 210
Kindler, E., Jónsdóttir, H. R., Muth, D., Hamming, O. J., Hartmann, R., Rodriguez, R., Geffers, R., Fouchier, R. A. M., Drosten, C., Müller, M. A., et al. (2013) · mBio · doi:10.1128/mbio.00611-12 · Cited by 202
Kono, M., Tatsumi, K., Imai, A. M., Saito, K., Kuriyama, T., & Shirasawa, H. (2007) · Antiviral Research · doi:10.1016/j.antiviral.2007.10.011 · Cited by 183
Chan, R. W. Y., Chan, M. C. W., Agnihothram, S., Chan, L. L. Y., Kuok, D. I. T., Fong, J. H. M., Guan, Y., Poon, L. L. M., Baric, R. S., Nicholls, J. M., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00009-13 · Cited by 178
Clinical management and infection control of SARS: Lessons learned
Cheng, V. C., Chan, J. F., To, K. K., & Yuen, K. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.08.016 · Cited by 176
Raj, V. S., Smits, S. L., Provacia, L. B., van den Brand, J. M. A., Wiersma, L., Ouwendijk, W. J. D., Bestebroer, T. M., Spronken, M. I., van Amerongen, G., Rottier, P. J. M., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02935-13 · Cited by 173
Self-citationZielecki, F., Weber, M., Eickmann, M., Spiegelberg, L., Zaki, A. M., Matrosovich, M., Becker, S., & Weber, F. (2013) · Journal of Virology · doi:10.1128/jvi.03496-12 · Cited by 158
Corman, V. M., Kallies, R., Philipps, H., Göpner, G., Müller, M. A., Eckerle, I., Brünink, S., Drosten, C., & Drexler, J. F. (2013) · Journal of Virology · doi:10.1128/jvi.01600-13 · Cited by 153
Chloroquine: Modes of action of an undervalued drug
Thomé, R., Lopes, S. C. P., Costa, F. T. M., & Verinaud, L. M. C. (2013) · Immunology Letters · doi:10.1016/j.imlet.2013.07.004 · Cited by 152
Ghosh, A. K., Takayama, J., Rao, K. V., Ratia, K. M., Chaudhuri, R., Mulhearn, D. C., Lee, H., Nichols, D. B., Baliji, S., Baker, S. C., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1004489 · Cited by 151
Full-Genome Deep Sequencing and Phylogenetic Analysis of Novel Human Betacoronavirus
Cotten, M. L., Lam, T. T., Watson, S. J., Palser, A. L., Petrova, V. N., Grant, P. R., Pybus, O. G., Rambaut, A., Guan, Y., Pillay, D., et al. (2013) · Emerging infectious diseases · doi:10.3201/eid1905.130057 · Cited by 150
Pneumonia from Human Coronavirus in a Macaque Model
Munster, V. J., de Wit, E., & Feldmann, H. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1215691 · Cited by 143
Kilianski, A., Mielech, A. M., Deng, X., & Baker, S. C. (2013) · Journal of Virology · doi:10.1128/jvi.02105-13 · Cited by 142
Coleman, C. M., Matthews, K. L., Goicochea, L., & Frieman, M. B. (2013) · Journal of General Virology · doi:10.1099/vir.0.060640-0 · Cited by 126
An Animal Model of MERS Produced by Infection of Rhesus Macaques With MERS Coronavirus
Yao, Y., Bao, L., Deng, W., Xu, L., Li, F., Lv, Q., Yü, P., Chen, T., Xu, Y., Zhu, H., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit590 · Cited by 125
Regnard, C., Twycross, R., Mihalyo, M., & Wilcock, A. (2011) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2011.06.001 · Cited by 117
Reverse Genetics of SARS-Related Coronavirus Using Vaccinia Virus-Based Recombination
van den Worm, S. H. E., Eriksson, K., Zevenhoven-Dobbe, J. C., Weber, F., Züst, R., Kuri, T., Dijkman, R., Chang, G., Siddell, S. G., Snijder, E. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032857 · Cited by 106
Self-citationPharmacology of Antidiarrheal Drugs
Awouters, F. H. L., Niemegeers, C. J. E., & Janssen, P. A. J. (1983) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.23.040183.001431 · Cited by 106
The management of coronavirus infections with particular reference to SARS
Wong, S. S. Y., & Yuen, K. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn243 · Cited by 101
Recent Developments in Anti-Severe Acute Respiratory Syndrome Coronavirus Chemotherapy
Barnard, D. L., & Kumaki, Y. (2011) · Future Virology · doi:10.2217/fvl.11.33 · Cited by 98
Evaluation of metal‐conjugated compounds as inhibitors of 3CL protease of SARS‐CoV
Hsu, J. T.-A., Kuo, C., Hsieh, H., Wang, Y.-C., Huang, K., Lin, C. P. C., Huang, P.-F., Chen, X., & Liang, P. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.08.015 · Cited by 94
Porotto, M., Orefice, G., Yokoyama, C. C., Mungall, B. A., Realubit, R. B., Sganga, M. L., Aljofan, M., Whitt, M. A., Glickman, J. F., & Moscona, A. (2009) · Journal of Virology · doi:10.1128/jvi.00164-09 · Cited by 93
Kumaki, Y., Wandersee, M. K., Smith, A., Zhou, Y., Simmons, G., Nelson, N. M., Bailey, K. W., Vest, Z. G., Li, J. K.-K., Chan, P. K. S., et al. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.02.003 · Cited by 92
Zheng, B., He, M., Wong, K.-L., Lum, C. T., Poon, L. L. M., Peng, Y., Guan, Y., Lin, M. C. M., & Kung, H. (2004) · Journal of Interferon & Cytokine Research · doi:10.1089/1079990041535610 · Cited by 77
Pharmacologic Treatment of SARS: Current Knowledge and Recommendations
Tai, D. Y. H. (2007) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v36n6p438 · Cited by 76
Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Tong, T. R. S.-W. (2009) · Infectious Disorders - Drug Targets · doi:10.2174/187152609787847659 · Cited by 61
Effect of chloroquine on feline infectious peritonitis virus infection in vitro and in vivo
Takano, T., Katoh, Y., Doki, T., & Hohdatsu, T. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.04.016 · Cited by 60
Pu, Y., & Zhang, X. (2008) · Journal of Virology · doi:10.1128/jvi.00837-08 · Cited by 54
Cervantes‐Barragán, L., Züst, R., Maier, R., Sierro, S. R., Janda, J., Lévy, F., Speiser, D. E., Romero, P. J., Rohrlich, P., Ludewig, B., et al. (2010) · mBio · doi:10.1128/mbio.00171-10 · Cited by 52
Neuroleptic Concentrations and Clinical Response
Rivera‐Calimlim, L., & Hershey, L. A. (1984) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.24.040184.002045 · Cited by 28
Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models
Paragas, J., Blatt, L. M., Hartmann, C. J., Huggins, J. W., & Endy, T. P. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.01.002 · Cited by 22
Therapies for coronaviruses. Part I of II – viral entry inhibitors
Tong, T. R. S.-W. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770802609384 · Cited by 22
Avian Infectious Bronchitis Virus Enters Cells Via the Endocytic Pathway
Chu, V. C., McElroy, L. J., Ferguson, A. D., Bauman, B. E., & Whittaker, G. R. (2006) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-33012-9_54 · Cited by 13
Soaring MERS Cases in Saudi Arabia Raise Alarms
Kupferschmidt, K. (2014) · Science · doi:10.1126/science.344.6183.457 · Cited by 12
Cited by
Characteristics of SARS-CoV-2 and COVID-19
Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00459-7 · Cited by 5,291
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,347
Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.008 · Cited by 2,330
Metadata
- Authors
- de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J., & Snijder, E. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-08
- Volume
- 58
- Issue
- 8
- Pages
- 4875-4884
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2139603860
- Cited by
- 736
- References
- 78
- FWCI
- 16.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.